Summarized by Masters of Longevity from Singularity Hub.
A human-interest science piece on an experimental cell therapy case, inviting readers to learn how researchers tested a bold CAR T approach in a young patient.
Key Takeaways
- Two outpatient infusions of autologous engineered CAR T cells produced a complete remission in a three-year-old with metastatic liver cancer.
- The CAR T cells were modified to express IL-15 and IL-21 for persistence and included a drug-activated kill switch for safety.
- The single-case outcome was published in the New England Journal of Medicine and the trial is actively recruiting patients aged one to 21.
